Northern Institute for Cancer Research

Cancer Drug Discovery

Cancer Drug Discovery

Developing novel targeted therapies for the treatment of cancer.

Cancer drug in a binding domain

We host one of four major Cancer Research UK small molecule drug discovery programmes in the UK. We specialise in applying structure-based methods to the identification of new cancer treatments.

Our vision

We're working to translate discoveries from basic and clinical research into new drugs against target proteins where there is little or no precedent.

We use state-of-the-art structural and biophysical methods. We combine these with expert medicinal chemistry to identify novel therapies.

We also carry out extensive studies to determine how to use each medicine optimally. We verify which patients are suitable for a particular treatment.

Areas of expertise

Our work within this research theme includes:

Our discoveries

 We’ve identified seven tool targeted compounds. These are available for use by the scientific community. These include the widely used NU7026 and NU7441 DNA-Dependent Protein Kinase (DNA-PK) inhibitors, and the first selective inhibitor of ataxia telangiectasia mutated (ATM) kinase.

To date, we've identified the following two compounds in clinical evaluation: